Premium
123 I‐metaiodobenzylguanidine scintigraphy in Parkinson's disease and related disorders
Author(s) -
Rascol Olivier,
Schelosky Ludwig
Publication year - 2009
Publication title -
movement disorders
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.352
H-Index - 198
eISSN - 1531-8257
pISSN - 0885-3185
DOI - 10.1002/mds.22499
Subject(s) - dementia with lewy bodies , pure autonomic failure , progressive supranuclear palsy , lewy body , parkinson's disease , atrophy , medicine , cardiology , rem sleep behavior disorder , dementia , orthostatic vital signs , psychology , pathology , disease , neuroscience , blood pressure
Autonomic dysfunction is common in Lewy body disorders (Parkinson's disease, Dementia with Lewy Bodies, Pure Autonomic Failure, and REM sleep disorder). The loss of post‐ganglionic myocardial sympathetic nerve fibers is a prominent feature of autonomic dysfunction in such disorders. 123 I‐metaiodobenzylguanidine (MIBG) scintigraphy that visualizes catecholaminergic terminals in vivo is a biomarker used to detect cardiac sympathetic degeneration. Abnormal MIBG uptake has been consistently reported in Lewy body disorders. Some studies agree in the notion that increasing bradykinesia is related with an incremental cardiac sympathetic denervation, whereas tremor is not closely linked to cardiac denervation. “Atypical” parkinsonian syndromes, including Multiple System Atrophy, Progressive Supranuclear Palsy, and others, show modest reductions of cardial MIBG uptake. MIBG scintigraphy is moderately sensitive and specific in differentiating Parkinson's disease from such syndromes. Conversely, its sensitivity and specificity might be better in cognitively impaired patients, helping differential diagnosis between Dementia with Lewy Bodies, and Alzheimer disease. Confounding factors (comorbidities, comedications) should be carefully controlled before analyzing MIBG scintigraphy. © 2009 Movement Disorder Society